Braxton Nottingham, MD
Family Medicine · Edmond, OKNPI 1821528480
Payments from drug & device makers
Across 297 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$745
- Lilly USA, LLC$559
- Novo Nordisk$517
- AstraZeneca$503
- Amgen$257
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,425100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 76 | $1,272 |
| Pfizer | 47 | $745 |
| Lilly USA, LLC | 36 | $559 |
| Novo Nordisk | 32 | $517 |
| AstraZeneca | 12 | $503 |
| Amgen | 15 | $257 |
| Boehringer Ingelheim | 8 | $164 |
| Nevro Corp. | 1 | $141 |
| Abbott | 7 | $133 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $122 |
| Dexcom, Inc. | 5 | $104 |
| Bayer | 6 | $100 |
| GSK | 5 | $77 |
| Exact Sciences | 4 | $71 |
| Merck | 4 | $69 |
| Tris Pharma Inc | 4 | $65 |
| Shield Therapeutics Inc | 2 | $63 |
| Ultragenyx Pharmaceutical Inc. | 3 | $59 |
| Mylan Specialty L.p. | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| SPR Therapeutics, Inc | 1 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Organon | 2 | $29 |
| Corium, LLC | 2 | $24 |
| Harmony Biosciences LLC | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Dynavax Technologies Corporation | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,433 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 224 | $304,482 |
| OzempicSemaglutide | 83 | $157,445 |
| JardianceEmpagliflozin | 104 | $135,473 |
| FarxigaDapagliflozin Propanediol | 89 | $110,160 |
| TrulicityDulaglutide | 80 | $109,197 |
| EliquisApixaban | 105 | $108,243 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 51 | $58,261 |
| Tresiba Flextouch U-200Insulin Degludec | 57 | $56,884 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $40,309 |
| SynjardyEmpagliflozin/Metformin Hcl | 20 | $31,918 |
| VraylarCariprazine Hcl | 18 | $29,666 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $20,070 |
| MyrbetriqMirabegron | 16 | $14,980 |
| AptiomEslicarbazepine Acetate | 11 | $13,635 |
| LinzessLinaclotide | 18 | $12,905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $559 | $413,678304 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Stiolto Respimat | $164 | $233,113189 claims |
| Novo NordiskOzempic | $517 | $157,44583 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $503 | $130,230117 claims |
| PfizerEliquis | $745 | $108,243105 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $77 | $50,26670 claims |
| AbbVieVraylar, Linzess, Synthroid | $1,272 | $44,86165 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $14,98016 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $34 | $13,63511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Edmond
- Stanley ShadidEdmond$363K
- Susan DimickEdmond$256K
- Charles WoodwardEdmond$15K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.